Shuting Xia

Associate Director, Biometrics
Isis Pharmaceuticals Inc.
Reduction of Hepatic Glucagon Receptor Expression with an Antisense Drug (ISIS-GCGRRX) Increases Total and Active GLP-1 Levels without Affecting Cholesterol or BP in Normal Subjects
FP17-3 ISIS Ptp-1BRx, a Novel Protein Tyrosine Phosphatase (PTP-1B) Antisense Inhibitor, Improves Both Insulin and Leptin Action and Increases HMW Adiponectin Levels in Obese Subjects
OR17-2 ISIS-GCCRRX, a Novel Glucocorticoid (GC) Receptor Antisense Drug Reduces Cholesterol and Triglycerides and Attenuates Dexamethasone Induced Hepatic Insulin Resistance without Systemic GC Antagonism in Normal Subjects